FindTrial
Sign In

Use of Trypsin and Chymotrypsin tablet in Injuries

A Cross-Sectional Study to Assess The Real World Utilization of Oral Trypsin:Chymotrypsin Enzymes In Management of Injuries (ARMOR Study) - ARMOR

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061594
Enrollment
3476
Registered
2024-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S00-T88- Injury, poisoning and certain other consequences of external causes

Interventions

Intervention1: NIL: NIL

Sponsors

Torrent Pharmaceuticals Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Male or female patients of 18 years or above 2) Patients with surgical or non-surgical injury or wound and treated with oral trypsin:chymotrypsin

Exclusion criteria

Exclusion criteria: Clinical case histories without patient ‘identifiers’ (viz. Name as Initials, Age, Gender, Height, Weight or BMI) and baseline scores for pain, edema or inflammation.

Design outcomes

Primary

MeasureTime frame
Safety assessment for very common Adverse Drug Reaction.Timepoint: From baseline Day 0 to 4 weeks—

Secondary

MeasureTime frame
1) Use of resucue medication as NSAID or Acetaminophen 2) Treatment choice for any class of compounds as initial or add-on therapy 3) Physicians global assessment on effectiveness and tolerabilityTimepoint: From baseline Day 0 to 4 weeks—

Countries

India

Contacts

Public ContactDr Rathish Nair PhD MBA

Torrent Pharmaceuticals Ltd

krishnaprasadkorukonda@torrentpharma.com7069000572

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026